Introduction
Mycotic aortic aneurysm (MAA) was coined by Sir William Osler in 1885, but is a misnomer for infection (usually bacterial) which degrades the aortic wall with subsequent aneurysm development.
1 MAA is a rare but life-threatening disease, with an incidence of about 0.65-2 % of all aortic aneurysms in western countries 2,3 and reportedly higher in east Asia. 4, 5 The disease carries a very poor prognosis as MAAs have a tendency to grow rapidly and to rupture; patients with MAA often have severe comorbidities, in particular immunodeficiency, and coexisting sepsis. 6, 7 Conventional surgical treatment with resection of the aneurysm, extensive local debridement, and revascularization by in-situ reconstruction or extra-anatomic bypass is the gold standard but carries a high mortality and morbidity. 8 Furthermore, the anatomical location of the aneurysm sometimes makes surgical repair very demanding, or even impossible. Reports on EVAR for MAA have shown promising results but only small single center case-series with limited follow-up have been published. 10, 11, 12, 13 The crucial question of durability therefore remains unanswered. The aim of this European multicenter collaboration was to study the durability of endovascular treatment of MAA, by assessing the late infection-related complications and long-term survival.
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Methods
All patients treated endovascularly for MAAs at 16 European centers from eight countries between 1999 and 2013 were identified. Participating centers are named in affiliations and described in Figure 1 .
An MAA was defined as a combination of the following three criteria: 1) clinical presentation (pain, fever, sepsis and/or concomitant infection), 2) laboratory tests (elevation of inflammatory markers like C-reactive protein and white blood cells, and/or positive cultures), and 3) radiological findings on computed tomography (CT) or magnetic resonance imaging (MRI) (rapid expansion of aneurysm, saccular aneurysm, multi-lobular aneurysms, eccentric aneurysms, periaortic gas and periaortic soft tissue mass). An infection-related complication was defined as recurrent sepsis, graft infection, aorto-enteric fistula or recurrence of a new MAA, in the same or at a different location.
All cases were retrospectively reviewed, applying a common study protocol (appendix A) including data on; 1) patient characteristics and clinical presentation (sex, age, medical history, immunodeficiency (including comorbidities and treatments associated with relative immunodeficiency), symptoms, concurrent infection, blood tests and microbiological cultures),
2) aneurysm characteristics (aneurysm status, location, CT-findings; rapid expansion, saccular, multilobular, periaortic gas, periaortic mass), 3) treatment (endovascular approach, extraanatomic hybrid procedure, bridge to open repair, antibiotic treatment (ABx)), and 4) follow-up time, outcome, and complications. All study protocols were sent to Uppsala for a secondary review (KS and AW). Cases treated with hybrid repair (combination of endovascular and open repair) were included if a stent graft was deployed in the infected field thus leaving the infected aneurysm in situ. Primary graft infections, aorto-enteric fistulae and graft-enteric fistulae were aneurysms, periaortic gas and periaortic soft tissue mass). An infection-related c com om omp pl p ic ic icat at atio io ion n n w was defined as recurrent sepsis, graft infection, aorto-enteric fistula f f or recurrence of a new MAA, in h he e sa sa sam me me o o or r r at at a a d d dif if iffe f rent location.
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Results
A total of 134 cases were identified and eleven were excluded; primary graft infections (n=6), primary aorto-enteric fistulae (n=2), and when an infectious pathogenesis could not be verified (n=3). Thus, a total of 123 patients treated for an MAA by means of endovascular technique were included in the study. 
Outcome
The mean follow-up time was 35 months (median 20, range 1 week-149 months). According to a
Kaplan-Meier analysis 1-month survival was 91% (95% CI 86-96%), 3-month 86% (80-92%), 1-project.org). A p-value <0.05 was considered significant.
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The 5-year survival of patients with immunodeficiency was 40% (95% CI 20-60%), with infection-related complications as the cause of death in 64% (16/25) of which nine (56%) occurred after 90-days. The subgroup of twelve patients with periaortic/intrathrombus gas on preoperative CT-scan had a 5-year survival rate of 36% (95% CI 0-72%), all deaths were infection-related of which four (67%) occurred after 90-days.
Six patients (5%) were later converted to open repair within a time span of three days to 15 months, due to graft infection (n=2), aorto-enteric fistula (n=1), type I endoleak (n=1), recurrent MAA (n=1) and unknown cause (n=1). Two of these patients survived the open repair conversion. Thirteen patients (11%) required endovascular reoperation from one day until 24 months of follow-up. Nine for type I endoleak; seven successfully treated with stentgraft extension and one with balloon-dilatation only. One patient with a type I endoleak died from cardiac arrhythmia during the initial phase of the attempted re-intervention. Two patients were successfully treated for type II endoleak; one with coiling and one with onyx embolization. Two patients had a type III endoleak; one presented with rupture after 24-month and was successfully treated with a cuff. The other presented with rupture after 18-months, was treated with a stentgraft extension, but died from multiorgan failure after 6 weeks. R Rep po ports on lon ng-g--te e erm m o out ut utco co come me me a aft ft ter er er o op pe pen n re epa pa air a are re sc car ar arce ce. T Th The e re repo port rted ed e 2 2-y -y ye ea ear r su su urv rv viv iv i al al i i is s a ab a o o out 60 0 0% % % 8,1 8, 8 6 6 an and d d a a a 5-5-y y yea ar ar s su ur urv vi viv val l ra rate te te of of of 3 35% 5% 5% w w wa as a r r rep ep epor or ort ted d d fr fr from om om a a a G G Ge e erm rm man an a si in ingl gl le e e c ce cent nt ter er er stu tu udy dy y o on n n 3 33 33 patients. 6 6 6 Lat ate e e gr gr graf af aft t t in in nfe fe ectio io ions ns ns o o occ cc ccu u urr rr r ed d d i in n n 7-7-7 10 10 10% % % of of of t the he e c c cas as ases es e However, an important difference between patients with a primary infected aneurysm and patients with a degenerative non-infected aneurysm is that the former are considerably younger (mean 69 year vs 74-78 year), and also probably have less comorbidities related to peripheral vascular disease and atherosclerosis.
Salmonella aortitis is a known complication of infection with Salmonella, which has a proclivity to adhere to vascular endothelium, especially if it is diseased by atherosclerosis. 22 Marked geographical microbial differences exist with Salmonella enteritidis being more dominant in Europe, but less common in Asia, where the variety of circulating serotypes are greater. 23 Salmonella infections are much more common in East Asia where most MAAs are caused by non-typhoidal Salmonella. 8, 14, 16, 24, 25 Salmonella-related aneurysms are known to have a fast disease progression with risk of early rupture. 8, 9, 26 After the initial postoperative period with high mortality, Salmonella positive patients had a favourable long-term outcome in the present report, which may be attributed to the effectiveness of modern ABx. 22 Non-Salmonella positive blood culture was the main factor associated with serious late complications in the present report, an observation supported by previous smaller reports. 8, 19, 26, 27 The duration and choice of ABx-therapy is an important matter for debate. Some authors recommend parenteral or oral ABx for at least six weeks. 11 A significant proportion of those developing late fatal infection-related complications did so after discontinuing ABx-therapy.
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Limitations
The retrospective design of this study is a limitation with risk of selection bias. However, during the study time-period only a handful of patients with MAAs were treated with open repair in the contributing centers, which suggests that this bias is minimal.
It is important to distinguish between primary infections of the native aorta (i.e. an MAA) from secondary aortic infections, such as graft infections, aortoenteric fistulaes, as well as inflammatory aneurysms. The definition of an MAA, as an aneurysm with proven bacterial infection in the aortic wall, however, creates an inherent limitation in studies of this disease, especially when treated endovascularly where bacterial culture from the aortic wall cannot be n these patients, or a bridge to later elective radical open surgery, once the patien en nt ha ha h s s s re e reco co cove ve v re r d from the initial emergency. However, this strategy was rarely adopted in this series. A few were co onv nv nver er erte te ted d d to to to e eme me erg rg rge ency open repair for life-thre e ea at ate en ning complica ati ti t ons, s, w w while most patients were ei ith h her e too wel ll l to to o jus usti ti tify fy a a m m maj aj ajor or o o ope pe pen n pr pr roce ed du u ure, or r r we e er re re t too oo oo f fra ra agi gile le to to o w w wit iths hs hst ta tand nd d su uc uch h h an n n op oper er e at at atio io i n. n. With few events (deaths), the precision of estimates (hazard ratios) is poor and the power to detect risk factors with moderate effects is low. Thus, the current risk factor analysis is susceptible to type-II statistical errors. It is also likely that a Cox model underestimates the effect COPD; chronic obstructive pulmonary disease. 1) Multiple MAA; descending aorta and infrarenal aorta (n=3), aortic arch and infrarenal aorta (n=2), descending aorta and paravisceral aorta (n=1), and paravisceral and infrarenal aorta (n=1). 2) Adjunctive endovascular procedures; chimney to the left carotid artery (n=1) or coil embolization of the left subclavian artery (n=1), the coeliac artery (n=1), or the hypogastric artery (n=2).
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